CBER’s 2018 Guidance Agenda Features Gene Therapies, Blood Products

Drug Industry Daily
A A
CBER’s agenda for 2018 states that it is considering the release of more than a dozen guidance documents, including new draft guidance on testing retroviral gene therapy products and on hemophilia gene therapy, along with revisions to its draft guidance on reducing the risk of Zika virus transmission.

To View This Article:

Login

Subscribe To Drug Industry Daily